Global Absorbable Surgical Sutures Market 2026 – 2035

The difference between the absorbable surgical suture industry size in the world is estimated to grow by USD 3.8 billion in 2025 and is projected to grow by USD 4.1 billion in 2026 to about USD 7.9 billion by 2035 with a 7.6% CAGR during 2026-2035. The rising number of surgical operations throughout the world, the heightened incidence of chronic attacks that need surgical maintenance, the laying down of minimal invasive surgery on a tablet, technological innovation in the field of suture materials with improved biocompatibility and absorption characteristics, and the growth of healthcare infrastructure in the developing markets are driving market development.

Market Highlight

• North America had the largest market share of absorbable surgical sutures at 38.5% in 2025.

• Asia Pacific will experience the quickest CAGR of 9.2% in the coming years, 2026-235.

• By the type of material, synthetic absorbable suture segment had about 72.4% of the market share in 2025.

• By type of material, the natural absorbable suture segment is expanding at a constant CAGR of 6.3% between the years 2026 and 2035.

• Application wise, the general surgery segment will provide the greatest market share of 31.7% in 2025, and the cosmetic and plastic surgery segment will have the highest CAGR of 9.8% in the estimated period between 2026 and 2035.

• By end user, the hospitals segment will have a market share of 64.2% in the year 2025 whereas ambulatory surgical centers are expected to have a CAGR of 8.9% in the forecast period.

• By distribution channel, direct sales contributed 56.8% in the market in 2025, and online platforms are projected to record the highest growth with a CAGR of 11.3% between 2026 and 2035.

Significant Growth Factors

The Absorbable Surgical Sutures Market Trends present significant growth opportunities due to several factors:

• Escalating Global Surgical Volume and Chronic Disease Burden: The massive expansion of surgery procedures carried out across the world is the real catalyst that is driving the market of absorbable sutures. It has been reported that some 312 million surgical operations are carried out globally every year and that it is expected to increase to 395 million by 2030 due to population growth, ageing populations, and an increase in surgical access in developing countries (The Lancet Commission on Global Surgery, 2024). WHO estimates that there are 5 billion people in the world that do not access safe and affordable surgical care and efforts to bridge this gap can be seen to dramatically raise the surgical volumes in low- and middle-income countries over the coming decade. The growing population of the aged in the world (between 65-94 years of age) is compelling more surgical operations such as joint replacement, hernia repair, cataract surgeries and other age-related suture activities, which boost the consumption of absorbable sutures.

• Advancement in Minimally Invasive Surgery and Laparoscopic Techniques: The adoption of Minimally invasive surgical (MIS) techniques such as laparoscopic, robotic-assisted and endoscopic surgeries has been a fundamental change in the patterns of surgical practice and has led to a significant demand for specialized absorbable sutures optimized for these techniques. According to the results of the market research, the proportion of minimally invasive procedures to the eligible surgical interventions has reached between 45% and 50% in developed markets, with the rate of adoption growing by 8-12% per annum with the advancement of technology, better training in the profession, and change in preferences of the patients towards the less invasive procedures, which have lower pain, shorter hospitalization, and shorter recovery periods. The introduction of single-incision laparoscopic surgery (SILS) and natural orifice transluminal endoscopic surgery are new frontier procedures, with a demand for ultra-specialized absorbable sutures with high flexibility and low tissue reactivity, which promotes further product innovation and high pricing prospects among production companies developing new materials.

What are the Major Advances Changing the Absorbable Surgical Sutures Market Today?

• Antimicrobial and Antibacterial Coating Technologies: Activities in the development and commercialization of the absorbable sutures with antimicrobial agents, especially triclosan-coated products, are an important innovation in the prevention of surgical site infection (SSI). The incidence of surgical site infections is about 2-5% of patients undergoing a surgical operation and the rate of SSI-hospital-acquired infections is 400,000-500,000 cases annually in the United States alone with the resultant healthcare expenditure of over 3.5-10 billion and the incidence of higher mortality rates. According to the research published in The Lancet Infectious Diseases, clinical meta-analyses of more than 15,000 patients show that triclosan-coated absorbable sutures decrease the incidence of surgical site infections by 30-40% relative to regular sutures, with especially significant effects of 35%, 43%, and 36% reduction in surgical site infections in colorectal surgery, cardiac surgery, and abdominal surgery, respectively. The antibacterial coating discharges therapeutic elements on the site in 7-14 days, reaching great tissue concentrations that repel bacterial colonization with minimal absorption to the system and minimal antibiotic resistance issues. In addition to triclosan, the next generation of antimicrobial coating solutions using silver nanoparticles, chlorhexidine, and new antimicrobial peptides are currently in clinical development with initial good evidence of potentially better efficacy profiles. Various antimicrobial absorbable suture items have been sanctioned by regulatory organizations such as the FDA and EMA and are being widely applied to surgical patients who are at high risk of SSI including diabetic patients, immunocompromised patients and dirty operating rooms where the likelihood of the patient developing SSI is 3-5 times greater than when the procedure is clean.

• Barbed and Knotless Suture Innovations: Barbed suture technology, which involves microscopic barbs carved into the surface of the suture, which clamps the tissue without the need to tie a knot, is an innovative and revolutionary technology that simplifies surgical closure and may help to improve outcomes. These knotless sutures save 20-35% of the time taken in pickup operations by time-motion studies and are especially beneficial in laparoscopic and robotic assisted surgeries where intracorporeal knot-tying is both impractical and time-consuming. The application of barbed sutures in plastic surgery shows that it produces the same or better cosmetic results than traditional sutures and saves an average of 8-12 minutes per surgery, which is a major direct benefit operationally and economically when applied in large surgical hospitals. Barbed absorbable sutures have demonstrated promising outcomes in orthopedic surgery in terms of tendon repairs, arthroscopic surgeries, and soft tissue approximation with biomechanical testing showing tensile strength equal to that of standard sutured repairs with the omission of knot related complications such as bulk prominence, knot migration, and local stress concentration.

• Enhanced Absorption Profiles and Strength Retention Engineering: Synthetic absorbable sutures of modern technology have applied high-tech polymer chemistry to design specific absorption curves and strength retention properties to meet the needs of a specific surgical procedure and tissue healing schedule. Conventional catgut sutures have random absorption resulting in total loss of tensile strength in 7-14 days whereas modern synthetic sutures such as polyglycolic acid (PGA), polylactic acid (PLA), polyglactin (Vicryl), polydioxanone (PDS), and poliglecaprone (Monocryl) have predictable degradation profiles. Polyglactin 910 sutures have tensile strength that at 2 weeks is around 75% and at 3 weeks is around 50%, with full absorption achieved at 56-70 days making it suitable for soft tissue approximation in general surgery. Today, manufacturers also provide product portfolios that feature 8-12 different absorption profiles so that surgeons can match suture properties to tissue biology, healing rates and mechanical loading needs with a precision never seen before, leading to better outcomes and less complication due to premature loss of strength or, over time, the unnecessary prolonged presence of a foreign body.

• Bioactive and Drug-Eluting Suture Technologies: The incorporation of bioactive substances to create absorbable suture matrices and pharmaceutical compounds into absorbable suture matrices is a new frontier that is changing sutures to an active system of therapeutic delivery and not only wound closure. Basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) growth factor-eluting sutures have been shown to stimulate faster wound healing, greater angiogenesis, and tissue regeneration in preclinical models and have been shown to improve clinical healing rate in chronic wounds and compromised tissues 25-40 times faster. Though the majority of drug-eluting suture technologies are still in research and development, some have already gone through clinical trials, and commercialization in the market is expected in 2026-2028, which could bring a high-value suture sector of between USD 400-600 million per year within 5-7 years of launch.

Category Wise Insights

By Material Type

Why Synthetic Absorbable Sutures Dominate the Market?

The synthetic absorbable category of sutures is currently the leading segment of the absorbable surgical sutures market and has the highest market share, 72.4%, due to their outperforming and predictable performance properties over natural counterparts. Synthetic polymers such as polyglycolic acid (PGA), polyglactin 910, polydioxanone (PDS), and poliglecaprone provide specifically designed rates of absorption with known strength retention schedules, about as short as 42-56 days and as long as 180-210 days, that allow surgeons to use the best products to match tissue types and healing needs. Clinical evidence shows that synthetic absorbable sutures have 40-60% greater initial tensile strength than natural catgut sutures of the same size, so that smaller caliber materials can be used to produce less tissue trauma than standard size catgut sutures and still provide adequate support to the wound.

Natural absorbable sutures, which are majorly made of catgut (plain and chromic) and collagen-based materials, command a decreasing yet significant market share of about USD 1.05 billion in 2025, which is concentrated in low-income markets, limited clinical uses where faster absorption rates are required and areas with limited access to higher end varieties. Plain catgut which is absorbed under enzyme degradation conditions between 7 and 14 days with full loss of strength in 7-10 days is still used in the repair of mucous membranes, episiotomy repair, and ophthalmic surgery where the shortest range of duration of foreign body is desired. Chromic catgut, impregnated with chromium salts to retard absorption to 21-28 days, is still in use in gynecology, urology surgery and in developing markets where cost is more important than synthetic performance. The market research reports that the natural suture prices are lower by an average of 0.5-2.00/unit than synthetic counterparts that are priced 2.5-8.00/unit, which is cost-effective within high amount, cost-limited healthcare systems especially in South Asia, Sub-Saharan Africa and some parts of Latin America, where natural suture consumption is 35-45 of the total absorbable suture consumption as opposed to 15-20 in developed nations.

By Application

Why General Surgery Leads Absorbable Sutures Applications?

The most applicable segment of the absorbable surgical suture is in general surgery, which has 31.7% of the market share in 2025, and varies in terms of procedures, such as gastrointestinal operations, hernia repair, abdominal surgery, appendectomy, cholecystectomy, and soft tissue closures which are conducted in almost all surgical settings. The World Health Organization approximates that about 85-95 million general surgical procedures are carried out every year in all countries around the globe, with each operation utilizing an average of 4-8 packages of absorbable sutures (between USD 15 and 50 a procedure) in multiple layers of tissue peritoneum, fascia, muscle, subcutaneous tissue, and skin. One of the most performed procedures in the world with more than 1.8 million cases per year in the developed world alone, laparoscopic cholecystectomy typically employs the use of 3-5 units of absorbable suture to close port sites, for fascial re-approximation, and for possible bile duct repairs, and it creates a market segment worth about USD 85-120 million annually. Hernia repair, which is being done 20 million times annually worldwide as per surgical database studies, is adopting absorbable sutures to fix tissues and fix mesh in tension-free repair and with each inguinal, femoral, umbilical, or incisional hernia repair costing USD 25-75 in absorbable suture materials. A notable use of suture-intensive application with multilayer anastomoses and closures that demand 8-15 suture packages per case, colorectal surgery, such as cancer resections, inflammatory bowel disease resections, and diverticular disease resections (about 2.5 million cases each year worldwide), is a significant market value consideration since antimicrobial-impregnated sutures are exhibiting a significant benefit in reducing SSI (40-45% reduction in colorectal cases), which is driving their adoption despite the

The most rapidly expanding application area, which is projected to grow at 9.8% CAGR between 2026 and 2035, is cosmetic and plastic surgery, where the number of interventions performed on appearance continues to grow, consumer expenditure on cosmetic surgery and related procedures is increasing, social attitudes toward plastic surgery appear to be shifting in its favor, and the technology enhances the outcomes and shortens the recovery time. According to the International Society of Aesthetic Plastic Surgery (ISAPS), it is estimated that 30.2 million surgical and non-surgical cosmetic procedures were carried out worldwide in 2024 and this was 40% more than it was in 2019, and these surgical procedures included breast augmentation, liposuction, blepharoplasty, abdominoplasty, and rhinoplasty. The cosmetic procedures are given a premium priority on the aesthetic results, wound healing and scar reduction, which generates high demand for high-absorbable sutures with minimum tissue reactivity, ultra fine caliber and optimum tensile strength profiles. The cosmetic and plastic surgery industry is the segment of application with the greatest growth dynamics, especially in the Asian-Pacific, Middle East, and Latin American markets due to the rise of cosmetic surgery in the post-pandemic period, the social media shaping beauty ideals, barriers to accessing plastic surgeons decreasing under the impact of telemedicine interventions, and the increasing wealth of potential customers due to the growth of additional markets.

By End User

Why Hospitals Dominate as End Users?

In 2025, the largest end-user base of absorbable surgical sutures will be hospitals with 64.2% of market share, being the main locations of complex, high-acuity surgery demanding an extensive supply of perioperative resources and dedicated surgical teams. The World Health Organization estimates that there are about 18,000-20,000 hospitals around the world that have surgical facilities, which in total have more than 200 million patients annually in inpatient surgery. A high rate of absorbable suture use per facility is shown in teaching and academic medical centers, which directly exclude the general 5-8% of total hospitals, which, however, do 20-25% of complex surgery procedures, with large academic centers spending USD 200,000-500,000 yearly on various types of sutures across various surgical specialties. Hospitals have a centralized procurement system, where they usually negotiate with up to 2-3 core suppliers but have backup suppliers to maintain product continuity, and purchasing decisions are highly dependent on clinical efficacy data, the preferences of the surgeon, value analysis committee appraisals and the total cost-of-ownership analysis, not only considering the costs of purchasing a product but also complication rates, operating room utilization, and patient outcome.

The fastest-growing end-user segment is ambulatory surgical centers (ASCs), which are expected to grow at 8.9% CAGR between 2026 and 2035 due to the trend toward healthcare delivery model development, where outpatient surgery is selected, cost containment pressures, the capability to perform surgery and discharge the same day, and the preference of patients for convenient and focused surgical facilities. In the US alone, more than 6,100 Medicare-certified ASCs offer about 28 million procedures per year (out of 55-60% of all possible outpatient surgeries), and ASC growth curves are taking a comparable upward path in Europe, Australia and in some areas of the Asian market. ASCs are mainly centered on large volume, low complexity procedures such as ophthalmology (cataract surgery represents 40-45% of ASC case volume), gastroenterology (colonoscopy and endoscopy), orthopedics (arthroscopy, hand surgery), podiatry, pain management, and plastic surgery, and absorbable sutures are being heavily promoted in these areas in terms of closure and tissue approximation.

By Distribution Channel

Why Direct Sales Lead Distribution Channels?

The leading channel of distribution of absorbable surgical sutures is direct sales, which comprise 56.8% of the market share in 2025, where the product is distributed directly by the sales representatives of the manufacturer to hospitals, surgical centers, and specialty practices to offer product education, clinical support, and relationship management. Large producers such as Johnson & Johnson (Ethicon), Medtronic, B. Braun and Smith and Nephew have sales forces of 500-2,000 representatives worldwide and territory assignments of 8-15 accounts assigned to each representative enabling the salesperson to visit the facility frequently, engage with surgeons, and provide quick and responsive answers to clinical questions or supply requests. Direct sales models give maximum control to the manufacturer on the brand messages and clinical positioning strategies and prices and allow complex services such as in-operating-room product tests, specialized surgeon training courses, value assessment support, and fast time-to-market product introduction. The direct channel is especially successful with higher-end products such as antimicrobial-coated sutures and barbed products and where clinical distinction and surgeon education are more important factors than price competition.

Online platforms will experience the highest growth rate with 11.3% CAGR between 2026 and 2035 as a result of the distribution channel's digital transformation in healthcare procurement, the acceleration of the adoption of e-commerce due to the COVID-19 pandemic, competitive shopping through price transparency, and the convenience of 24/7 ordering with direct-to-facility delivery. The E-commerce platforms such as Amazon Business Medical, Walmart Healthcare, and even the direct divisions of specific suppliers like Medex Supply and Med-Vet International have now started to provide absorbable suture products and are competing to offer their offerings to small practices, veterinary clinics, international customers, and those who are cost conscious and seek an alternative to traditional distribution methods. Online channels prove to be especially effective in commodity suture products with little clinical distinction and where price is the key shopping factor where an online price tends to be 20-40% lower than a hospital contract price amid lower distribution expense and direct-to-manufacturer delivery.

The greatest portion of the world market of absorbable surgical sutures is occupied by North America, which takes 38.5% of the total amount of revenue in 2025 due to the high rates of surgical procedures, well-developed healthcare infrastructure, high rates of innovation technologies acceptance, good reimbursement climate, and the presence of large manufacturing corporations in the industry. The U.S. accounts for 85-87%. consumption of the absorbable sutures in North America and Canada and Mexico forms the rest. The American College of Surgeons estimates that about 48 million operations are done each year in the US, including 6-10 absorbable suture packages on average in the inpatient surgery case and 2-4 packages on outpatient surgery procedures, which leaves a huge market demand. The US market also boasts of good intellectual property guarantees, good clinical research facilities generating evidence of the emerging technologies, and direct-to-consumer advertising (where allowed), which creates awareness among patients and spurs demand for high-level surgical supplies.

Report Scope

Regional Analysis

How Big is the North America Absorbable Surgical Sutures Market Size?

The North America absorbable surgical sutures market size is estimated at USD 1.46 billion in 2025 and is projected to reach approximately USD 2.68 billion by 2035, with a 6.3% CAGR from 2026 to 2035.

Why did North America Dominate the Absorbable Surgical Sutures Market in 2025?

It is expected that the wearable sutures market will have the fastest growth with a CAGR of 9.2% between 2026 and 2035 due to the fast-growing volumes of surgical operations, the growth in healthcare infrastructure, the growth in healthcare spending, the growth in medical tourism, the improvement in insurance coverage, and the increase in the use of advanced surgical procedures. Growth in the surgical demand has been tremendous due to the huge population base of 4.7 billion people (59% of the world population) in the region, increasing incomes, urbanization, as well as epidemiological changes in the region towards chronic diseases that are surgical in nature.

What is the Size of the U.S. Absorbable Surgical Sutures Market?

The U.S. absorbable surgical sutures market has been estimated at USD 1.25 billion in 2025 and projected to almost USD 2.29 billion in 2035 with a tremendous CAGR of 6.2 in the period between 2026 and 2035.

U.S. Absorbable Surgical Sutures Market Trends

The US absorbable sutures market has a number of unique trends such as the trend towards continued substitution with synthetic products, a growing use of antimicrobial-coated products due to hospital-acquired infection reduction programs and CMS (Centers for Medicare & Medicaid Services) penalties on excessive surgical site infections, increased use of barbed sutures especially in cosmetic surgery, gynecology, and orthopedic sports medicine procedures where barbed sutures have penetrated. There has been a sharp increase in group purchasing organization (GPO) consolidation, where the three largest GPOs (Premier, Vizient, and HealthTrust), currently controlling more than 60% of US hospital purchasing volume, have created a pressure on prices, as well as offered vendors an efficient channel to access the market by gaining a preferred formulary position.

Why is Asia Pacific Experiencing the Fastest Growth in the Absorbable Surgical Sutures Market?

The Asia-Pacific region is projected to exhibit the fastest growth in the absorbable surgical sutures market, expanding at a CAGR of 9.2% from 2026 to 2035, driven by rapidly increasing surgical volumes, expanding healthcare infrastructure, rising healthcare expenditures, growing medical tourism, improving insurance coverage, and increasing adoption of advanced surgical techniques. The region's massive population base of 4.7 billion people (59% of the global population), combined with rising incomes, urbanization, and epidemiological transition toward chronic diseases requiring surgical intervention creates enormous surgical demand growth.

China Absorbable Surgical Sutures Market Trends

The Asia Pacific market is the biggest and fastest-growing absorbable sutures market with China increasing from USD 420 million (2025) to USD 1.08 billion (2035) at a 9.9% CAGR. Approximately 65 million surgeries are done every year in 35,000+ hospitals. Healthcare reforms, coverage above 95 and higher hospital capacity in the lower tier cities and robust domestic manufacturing have been driving growth. Local manufacturers sell sutures at 40-60% of the price of global brands and keep on continuously improving in quality, accessibility, and market penetration.

Why is Europe Entering a New Era of Absorbable Surgical Sutures Market?

Europe holds 27–29% of the global market, valued at USD 1.04 billion in 2025 and projected to reach USD 1.89 billion by 2035 (6.2% CAGR). Growth is driven by aging populations, high surgery volumes, infection-prevention focus, and minimally invasive surgery adoption. The EU MDR regulation raises compliance requirements, favoring established manufacturers. Antimicrobial sutures have 20–25% penetration, reflecting Europe’s balanced focus on outcomes, cost-effectiveness, and antimicrobial stewardship.

Germany Absorbable Surgical Sutures Market Trends

Germany is the biggest European market with USD 245 million in 2025 with an annual 16.5 million surgeries, good hospital infrastructure, and domestic manufacturers like B. Braun. The system rewards innovations that have been proven clinically and promotes the use of premium products that have been found cost-effective. Conservative adoption is the adoption of new technologies that have strong evidence, but once adopted, they will be highly loyal. The cardiac, neurosurgery and cancer industries are particularly in need, especially as performance demands are superior.

Why is the Middle East & Africa Region Accelerating Use of Absorbable Surgical Sutures?

The MEA market is projected at USD 285 million (2025) and will go up to USD 570 million (2035) at the CAGR of 7.1%. Hospitals, medical tourism, and surgical capacity are growing in the Gulf countries such as Saudi Arabia, UAE and Qatar. The African region is experiencing key challenges such as a lack of surgical access and funds to be used for simple materials. Nonetheless, increasing incomes, urbanization and government spending on healthcare in other nations like Nigeria, Kenya, Egypt, and Ghana are slowly putting pressure on the demand for absorbable sutures.

Top Players in the Absorbable Surgical Sutures Market and Their Offerings

• Johnson & Johnson (Ethicon)

• Medtronic plc

• B. Braun Melsungen AG

• Smith & Nephew plc

• Boston Scientific Corporation

• 3M Company

• DemeTECH Corporation

• Surgical Specialties Corporation

• Internacional Farmacéutica S.A. de C.V.

• W.L. Gore & Associates

• Others

Key Developments

The Absorbable Surgical Sutures Market has witnessed many major developments whereby the industry players seek to innovate their products, internationalize in their geographical market, increase their manufacturing capacity, and seek strategic alliances to reinforce their competitive orientation.

• In July 2025, Corza Medical announced the launch of its expanded Onatec Ophthalmic Suture Portfolio. This extension of the products makes it easier for surgeons globally to choose the right Onatec suture solution for their ophthalmic procedures. (Source: Corza Medical)

• In May 2024, KKR an investment firm announced the acquisition of Healthium MedTech Ltd., an Indian medical devices company, from an affiliate of Funds advised by Apax Partners LLP. (Source: KKR)

These strategic operations have seen the companies put strong market positions, meet the emerging clinical requirements, build portfolios of products, and exploit growth opportunities in a wide and varied range of surgical specialties and geographic markets within the dynamic absorbable surgical suture business.

The Absorbable Surgical Sutures Market is segmented as follows:

By Material Type

• Natural Absorbable Sutures

o   Catgut (Plain)

o   Chromic Catgut

o   Collagen-based

• Synthetic Absorbable Sutures

o   Polyglycolic Acid (PGA)

o   Polylactic Acid (PLA)

o   Polyglactin (Vicryl)

o   Polydioxanone (PDS)

o   Poliglecaprone (Monocryl)

o   Polytrimethylene Carbonate (Maxon)

By Application

• Cardiovascular Surgery

• General Surgery

o   Abdominal Surgery

o   Gastrointestinal Surgery

o   Hernia Repair

• Gynecological Surgery

o   Cesarean Section

o   Hysterectomy

o   Pelvic Floor Repair

• Orthopedic Surgery

o   Soft Tissue Repair

o   Arthroscopic Surgery

o   Tendon/Ligament Repair

• Ophthalmic Surgery

• Cosmetic and Plastic Surgery

o   Reconstructive Surgery

o   Aesthetic Surgery

• Others

o   Dental Surgery

o   Urological Surgery

o   Pediatric Surgery

By End User

• Hospitals

o   Teaching/Academic Hospitals

o   Community Hospitals

• Ambulatory Surgical Centers

• Specialty Clinics

• Others

By Distribution Channel

• Direct Sales

• Medical Distributors

• Online Platforms

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America